Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapy
about
Cenicriviroc, a dual CCR2 and CCR5 antagonist leads to a reduction in plasma fibrotic biomarkers in persons living with HIV on antiretroviral therapy
description
scientific article published on 01 August 2019
@en
name
Cenicriviroc, a dual CCR2 and ...... HIV on antiretroviral therapy
@en
type
label
Cenicriviroc, a dual CCR2 and ...... HIV on antiretroviral therapy
@en
prefLabel
Cenicriviroc, a dual CCR2 and ...... HIV on antiretroviral therapy
@en
P2093
P1476
Cenicriviroc, a dual CCR2 and ...... HIV on antiretroviral therapy
@en
P2093
B L Mitchell
C Siriwardhana
D Ogata-Arakaki
L C Ndhlovu
L M A Gangcuangco
M L D'Antoni
P304
P356
10.1080/25787489.2020.1719319
P577
2019-08-01T00:00:00Z